Results 51 to 60 of about 12,875 (237)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries

Frontiers in Pharmacology, 2017
Objectives: The aim of this study was to review the requirements for the reimbursement of biosimilars and to compare the reimbursement status, market share, and reimbursement costs of biosimilars in selected Central and Eastern European (CEE) countries ...
Paweł Kawalec, Ewa Stawowczyk, Tomas Tesar, Jana Skoupa, Adina Turcu-Stiolica, Maria Dimitrova, Guenka I. Petrova, Zinta Rugaja, Agnes Männik, Andras Harsanyi, Andras Harsanyi, Pero Draganic   +11 more
doaj   +1 more source

Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand‐Alone Part D Plans

Arthritis &Rheumatology, EarlyView.
Objective We examine coverage of self‐administered disease‐modifying antirheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022–2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T cell costimulatory modulator, interleukin‐6 (IL ...
Youngmin Kwon, Robert W. Corty, Stacie B. Dusetzina   +2 more
wiley   +1 more source

Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double‐Blind, Proof‐of‐Concept Study

Arthritis &Rheumatology, EarlyView.
Objective To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi‐IR). Methods Adults with active TNFi‐IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) +
Jose U. Scher, Iain B. McInnes, Enrique R. Soriano, Joseph F. Merola, Paul Bird, Vinod Chandran, Edaire Cheng, Elena Reynoso, Warner Chen, Maoji Li, Lianne S. Gensler, Philip J. Mease, Christopher T. Ritchlin   +12 more
wiley   +1 more source

Biosimilars: A Multidisciplinary Perspective [PDF]

, 2016
A biosimilar is an officially regulated and approved copy of an originator biologic therapy. Improved affordability and consequent wider patient access compared with biologics are a significant appeal of biosimilars.
Lukas, Milan, Florian Scotte, Majed Khraishi, Schmid, Holger, David Stead, Scotte, Florian, Stead, David, Milan Lukas, Holger Schmid, Khraishi, Majed   +9 more
core   +1 more source

Nonmelanoma Skin Cancer Risk With JAK Inhibitors Compared to Interleukin‐6 Receptor Inhibitors in Rheumatoid Arthritis: Results From a National Cohort Study

Arthritis &Rheumatology, EarlyView.
Objective Nonmelanoma skin cancer (NMSC) is one of the most common malignancies in rheumatoid arthritis (RA). This analysis assessed NMSC risk with JAK inhibitors (JAKi) compared to interleukin‐6 receptor inhibitors (IL‐6Ri). Methods This study used data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis linked to the
Zixing Tian, Lianne Kearsley‐Fleet, Sizheng Steven Zhao, James Galloway, Mark Lunt, Kath Watson, Narges Azadbakht, British Society for Rheumatology Biologics Register in Rheumatoid Arthritis Contributors Group, Kimme L. Hyrich   +8 more
wiley   +1 more source

Biosimilars helfen sparen [PDF]

, 2023
Sie sind gleichwertig und kostengünstiger. Dennoch werden Biosimilars – die Nachahmerprodukte von Biologika – in der Schweiz bisher selten verordnet. Was sind die Gründe dafür?
Ccile Grobet, Renato Mattli, Mattli, Renato, Wieser, Simon, Grobet, Cécile, Simon Wieser   +5 more
core   +1 more source

Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany.

PLoS ONE, 2017
ObjectivesThis study examined gastroenterologists' motivation for prescribing biosimilars, assessed their treatment preferences in relation to prescribing behaviour, and explored patient attitudes to biosimilars.MethodsData were taken from the Adelphi ...
Emma Sullivan, James Piercy, John Waller, Christopher M Black, Sumesh Kachroo   +4 more
doaj   +1 more source

Biosimilars in the French and Polish System: Chosen Aspects of Reimbursement and Access

Comparative Economic Research, 2020
The EU approved the first biosimilar drug in 2006. By 2017, the EU had authorized the highest number of biosimilars worldwide, acquiring considerable experience in their use and safety.
Olga Barszczewska, Ralph Chami, Anna Piechota   +2 more
doaj   +1 more source

Biosimilar bidding in centralized tenders in Norway

Nordic Journal of Health Economics, 2021
Our objective is to study the competition effect of biosimilar entry in centralized tenders for an expensive category or drugs - TNF-inhibitors. We use monthly observations of prices and volumes for all brands and biosimilars in this drug category in ...
Dag Morten Dalen, Steinar Strøm, Marilena Locatelli   +2 more
doaj   +1 more source

Biosimilars in dermatology

Advances in Dermatology and Allergology, 2015
Over the last decade the availability of biological drugs for the treatment of psoriasis vulgaris, psoriatic arthritis and many other inflammatory diseases has revolutionized the treatment of these diseases around the world. Due to the high cost of therapy, the search has started for biosimilars.
Mazur, Małgorzata, Olek-Hrab, Karolina, Karczewski, Jacek, Teresiak-Mikołajczak, Ewa, Adamski, Zygmunt   +4 more
openaire   +2 more sources